http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 26 Feb 2026 16:05:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+March+12%2C+2026/26070404.html <p> MAHWAH, N.J.--(BUSINESS WIRE)-- <b>KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),</b> a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. </p><p> <b>Conference Call and Webcast Details</b> </p><p> The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+March+12%2C+2026/26070404.html Thu, 26 Feb 2026 16:05:00 -0500 KRMD O.00031240 http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+March+12%2C+2026/26070404.html <p> MAHWAH, N.J.--(BUSINESS WIRE)-- <b>KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),</b> a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. </p><p> <b>Conference Call and Webcast Details</b> </p><p> The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+March+12%2C+2026/26070404.html Thu, 26 Feb 2026 16:05:00 -0500 KRMD O.00031240 http://www.streetinsider.com/Business+Wire/KORU+Medical+Systems+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+March+12%2C+2026/26070404.html <p> MAHWAH, N.J.--(BUSINESS WIRE)-- <b>KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),</b> a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. </p><p> <b>Conference Call and Webcast Details</b> </p><p> The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. http://www.streetinsider.com/Business+Wire/KORU+Medical+Systems+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+March+12%2C+2026/26070404.html Thu, 26 Feb 2026 16:05:00 -0500 KRMD O.00031240 http://www.streetinsider.com/Business+Wire/KORU+Medical+Systems+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+March+12%2C+2026/26070404.html <p> MAHWAH, N.J.--(BUSINESS WIRE)-- <b>KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),</b> a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. </p><p> <b>Conference Call and Webcast Details</b> </p><p> The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. http://www.streetinsider.com/Business+Wire/KORU+Medical+Systems+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+March+12%2C+2026/26070404.html Thu, 26 Feb 2026 16:05:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26013997.html si-local-file:///var/storage/secattach/20260217/26013997.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26013997.html Tue, 17 Feb 2026 16:35:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26013997.html si-local-file:///var/storage/secattach/20260217/26013997.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26013997.html Tue, 17 Feb 2026 16:35:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Topline+Capital+Management%2C+LLC/26001939.html si-local-file:///var/storage/secattach/20260213/26001939.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Topline+Capital+Management%2C+LLC/26001939.html Fri, 13 Feb 2026 17:14:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Topline+Capital+Management%2C+LLC/26001939.html si-local-file:///var/storage/secattach/20260213/26001939.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Topline+Capital+Management%2C+LLC/26001939.html Fri, 13 Feb 2026 17:14:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Topline+Capital+Management%2C+LLC/26001941.html si-local-file:///var/storage/secattach/20260213/26001941.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Topline+Capital+Management%2C+LLC/26001941.html Fri, 13 Feb 2026 17:14:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Topline+Capital+Management%2C+LLC/26001941.html si-local-file:///var/storage/secattach/20260213/26001941.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Topline+Capital+Management%2C+LLC/26001941.html Fri, 13 Feb 2026 17:14:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Horton+Capital+Partners%2C+LLC/26001598.html si-local-file:///var/storage/secattach/20260213/26001598.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Horton+Capital+Partners%2C+LLC/26001598.html Fri, 13 Feb 2026 16:56:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Horton+Capital+Partners%2C+LLC/26001598.html si-local-file:///var/storage/secattach/20260213/26001598.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++KORU+Medical+Systems%2C++++++++++++++++++Filed+by%3A+Horton+Capital+Partners%2C+LLC/26001598.html Fri, 13 Feb 2026 16:56:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KORU+Medical+Systems%2C+++++For%3A+Feb+13++Filed+by%3A+Horton+Capital+Partners%2C+LLC/26001576.html si-local-file:///var/storage/secattach/20260213/26001576.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KORU+Medical+Systems%2C+++++For%3A+Feb+13++Filed+by%3A+Horton+Capital+Partners%2C+LLC/26001576.html Fri, 13 Feb 2026 16:54:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KORU+Medical+Systems%2C+++++For%3A+Feb+13++Filed+by%3A+Horton+Capital+Partners%2C+LLC/26001576.html si-local-file:///var/storage/secattach/20260213/26001576.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KORU+Medical+Systems%2C+++++For%3A+Feb+13++Filed+by%3A+Horton+Capital+Partners%2C+LLC/26001576.html Fri, 13 Feb 2026 16:54:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++KORU+Medical+Systems%2C+++++For%3A+Feb+05/25978668.html si-local-file:///var/storage/secattach/20260211/25978668.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++KORU+Medical+Systems%2C+++++For%3A+Feb+05/25978668.html Wed, 11 Feb 2026 06:04:00 -0500 KRMD O.00031240 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++KORU+Medical+Systems%2C+++++For%3A+Feb+05/25978668.html si-local-file:///var/storage/secattach/20260211/25978668.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++KORU+Medical+Systems%2C+++++For%3A+Feb+05/25978668.html Wed, 11 Feb 2026 06:04:00 -0500 KRMD O.00031240 http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html <p>KORU Medical Systems, Inc. (NASDAQ: KRMD) received U.S. Food and Drug Administration 510(k) clearance for its FreedomEDGE infusion system to deliver RYSTIGGO (rozanolixizumab-noli), a therapy for generalized myasthenia gravis.</p> <p>The clearance expands the FreedomEDGE label to include administration by healthcare professionals in clinical settings, in addition to existing home-based patient self-administration capabilities. RYSTIGGO, commercialized by UCB of Brussels, Belgium, treats adults with generalized myasthenia gravis, a chronic autoimmune disorder affecting nerve-muscle communication.</p> <p>The drug is administered as weekly subcutaneous infusions of 3-6 milliliters over 15-30 minutes for six weeks, with subsequent treatment cycles determined by clinical evaluation, according to the company statement.</p> <p>"With http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html Thu, 29 Jan 2026 16:05:26 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139 http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html <p>KORU Medical Systems, Inc. (NASDAQ: KRMD) received U.S. Food and Drug Administration 510(k) clearance for its FreedomEDGE infusion system to deliver RYSTIGGO (rozanolixizumab-noli), a therapy for generalized myasthenia gravis.</p> <p>The clearance expands the FreedomEDGE label to include administration by healthcare professionals in clinical settings, in addition to existing home-based patient self-administration capabilities. RYSTIGGO, commercialized by UCB of Brussels, Belgium, treats adults with generalized myasthenia gravis, a chronic autoimmune disorder affecting nerve-muscle communication.</p> <p>The drug is administered as weekly subcutaneous infusions of 3-6 milliliters over 15-30 minutes for six weeks, with subsequent treatment cycles determined by clinical evaluation, according to the company statement.</p> <p>"With http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html Thu, 29 Jan 2026 16:05:26 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139 http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html <p>KORU Medical Systems, Inc. (NASDAQ: KRMD) received U.S. Food and Drug Administration 510(k) clearance for its FreedomEDGE infusion system to deliver RYSTIGGO (rozanolixizumab-noli), a therapy for generalized myasthenia gravis.</p> <p>The clearance expands the FreedomEDGE label to include administration by healthcare professionals in clinical settings, in addition to existing home-based patient self-administration capabilities. RYSTIGGO, commercialized by UCB of Brussels, Belgium, treats adults with generalized myasthenia gravis, a chronic autoimmune disorder affecting nerve-muscle communication.</p> <p>The drug is administered as weekly subcutaneous infusions of 3-6 milliliters over 15-30 minutes for six weeks, with subsequent treatment cycles determined by clinical evaluation, according to the company statement.</p> <p>"With http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html Thu, 29 Jan 2026 16:05:26 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139 http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html <p>KORU Medical Systems, Inc. (NASDAQ: KRMD) received U.S. Food and Drug Administration 510(k) clearance for its FreedomEDGE infusion system to deliver RYSTIGGO (rozanolixizumab-noli), a therapy for generalized myasthenia gravis.</p> <p>The clearance expands the FreedomEDGE label to include administration by healthcare professionals in clinical settings, in addition to existing home-based patient self-administration capabilities. RYSTIGGO, commercialized by UCB of Brussels, Belgium, treats adults with generalized myasthenia gravis, a chronic autoimmune disorder affecting nerve-muscle communication.</p> <p>The drug is administered as weekly subcutaneous infusions of 3-6 milliliters over 15-30 minutes for six weeks, with subsequent treatment cycles determined by clinical evaluation, according to the company statement.</p> <p>"With http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html Thu, 29 Jan 2026 16:05:26 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139 http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html <p>KORU Medical Systems, Inc. (NASDAQ: KRMD) received U.S. Food and Drug Administration 510(k) clearance for its FreedomEDGE infusion system to deliver RYSTIGGO (rozanolixizumab-noli), a therapy for generalized myasthenia gravis.</p> <p>The clearance expands the FreedomEDGE label to include administration by healthcare professionals in clinical settings, in addition to existing home-based patient self-administration capabilities. RYSTIGGO, commercialized by UCB of Brussels, Belgium, treats adults with generalized myasthenia gravis, a chronic autoimmune disorder affecting nerve-muscle communication.</p> <p>The drug is administered as weekly subcutaneous infusions of 3-6 milliliters over 15-30 minutes for six weeks, with subsequent treatment cycles determined by clinical evaluation, according to the company statement.</p> <p>"With http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html Thu, 29 Jan 2026 16:05:26 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139 http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html <p>KORU Medical Systems, Inc. (NASDAQ: KRMD) received U.S. Food and Drug Administration 510(k) clearance for its FreedomEDGE infusion system to deliver RYSTIGGO (rozanolixizumab-noli), a therapy for generalized myasthenia gravis.</p> <p>The clearance expands the FreedomEDGE label to include administration by healthcare professionals in clinical settings, in addition to existing home-based patient self-administration capabilities. RYSTIGGO, commercialized by UCB of Brussels, Belgium, treats adults with generalized myasthenia gravis, a chronic autoimmune disorder affecting nerve-muscle communication.</p> <p>The drug is administered as weekly subcutaneous infusions of 3-6 milliliters over 15-30 minutes for six weeks, with subsequent treatment cycles determined by clinical evaluation, according to the company statement.</p> <p>"With http://www.streetinsider.com/FDA/KORU+Medical+gets+FDA+clearance+for+RYSTIGGO+drug+delivery+system/25916369.html Thu, 29 Jan 2026 16:05:26 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139 http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+Receives+FDA+510%28k%29+Clearance+for+Delivery+of+RYSTIGGO%C2%AE+%28rozanolixizumab-noli%29%2C+Expanding+Label+for+FreedomEDGE%C2%AE+Infusion+System/25916347.html <p> MAHWAH, N.J.--(BUSINESS WIRE)-- <b>KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),</b> a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy commercialized globally by UCB, Brussels, Belgium (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ucb.com&amp;esheet=54408221&amp;newsitemid=20260129815700&amp;lan=en-US&amp;anchor=www.ucb.com&amp;index=1&amp;md5=e8b785e0e3064c8b9031af6601335ed1" shape="rect">www.ucb.com</a>). </p><p> The clearance for the FreedomEDGE® label includes indicated administration by a healthcare professional, increasing flexibility and access for patients living with generalized myasthenia (gMG). http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+Receives+FDA+510%28k%29+Clearance+for+Delivery+of+RYSTIGGO%C2%AE+%28rozanolixizumab-noli%29%2C+Expanding+Label+for+FreedomEDGE%C2%AE+Infusion+System/25916347.html Thu, 29 Jan 2026 16:05:00 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139 http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+Receives+FDA+510%28k%29+Clearance+for+Delivery+of+RYSTIGGO%C2%AE+%28rozanolixizumab-noli%29%2C+Expanding+Label+for+FreedomEDGE%C2%AE+Infusion+System/25916347.html <p> MAHWAH, N.J.--(BUSINESS WIRE)-- <b>KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),</b> a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy commercialized globally by UCB, Brussels, Belgium (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ucb.com&amp;esheet=54408221&amp;newsitemid=20260129815700&amp;lan=en-US&amp;anchor=www.ucb.com&amp;index=1&amp;md5=e8b785e0e3064c8b9031af6601335ed1" shape="rect">www.ucb.com</a>). </p><p> The clearance for the FreedomEDGE® label includes indicated administration by a healthcare professional, increasing flexibility and access for patients living with generalized myasthenia (gMG). http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+Receives+FDA+510%28k%29+Clearance+for+Delivery+of+RYSTIGGO%C2%AE+%28rozanolixizumab-noli%29%2C+Expanding+Label+for+FreedomEDGE%C2%AE+Infusion+System/25916347.html Thu, 29 Jan 2026 16:05:00 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139 http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+Receives+FDA+510%28k%29+Clearance+for+Delivery+of+RYSTIGGO%C2%AE+%28rozanolixizumab-noli%29%2C+Expanding+Label+for+FreedomEDGE%C2%AE+Infusion+System/25916347.html <p> MAHWAH, N.J.--(BUSINESS WIRE)-- <b>KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),</b> a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy commercialized globally by UCB, Brussels, Belgium (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ucb.com&amp;esheet=54408221&amp;newsitemid=20260129815700&amp;lan=en-US&amp;anchor=www.ucb.com&amp;index=1&amp;md5=e8b785e0e3064c8b9031af6601335ed1" shape="rect">www.ucb.com</a>). </p><p> The clearance for the FreedomEDGE® label includes indicated administration by a healthcare professional, increasing flexibility and access for patients living with generalized myasthenia (gMG). http://www.streetinsider.com/Press+Releases/KORU+Medical+Systems+Receives+FDA+510%28k%29+Clearance+for+Delivery+of+RYSTIGGO%C2%AE+%28rozanolixizumab-noli%29%2C+Expanding+Label+for+FreedomEDGE%C2%AE+Infusion+System/25916347.html Thu, 29 Jan 2026 16:05:00 -0500 A.06822034 A.18955402 KRMD O.00031240 O.20026344 O.39153139